Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by JDavenporton Nov 10, 2020 8:55am
373 Views
Post# 31869056

Denali gets it done. So can Bioasis.

Denali gets it done. So can Bioasis.Today, Denali Therapeutics announced that "biomarker proof of concept was achieved for its Transport Vehicle (TV) technology in a Phase 1/2 study of ETV:IDS (DNL310) for the potential treatment of Hunter syndrome (MPS II)."

Denali also stated in the press release, "“The robust reduction in cerebrospinal fluid (CSF) GAG levels observed after only four weeks of treatment with DNL310 in the Phase 1/2 study exceeded our initial goal in both magnitude and timing of heparan sulfate reduction after treatment,” said Carole Ho, M.D., Denali’s Chief Medical Officer."

These clinical trial results from Denali are with the Lysosomal Storage Disease, MPS II, Hunter Syndrome, the same disease that Bioasis' pipeline candidate, xB3-008, is designed to treat.

These results show proof of concept of not only a treatment for Hunter Syndrome, but also proof of concept that the delivery of therapeutics across the blood-brain barrier by receptor mediated transport (RMT) is likely to work across broad spectrums of diseases and therapeutics. This Denali press release mirrors the results that Bioasis achieved with Scarpa's studies as well as other Bioasis proof of concept studies in years past.

Denali yesterday closed at  USD $55.81. With 120 million shares outstanding, Denali now has a market cap of USD $6.7 billion. Remember that number as we watch Denali climb further with this striking news. Bioasis now has a market cap of CDN $24 million, or USD $18.48 million. Think about this. Every change of USD $0.154 (USD 15.4¢) represents a change in Denali's market cap equal to our entire market cap. Every 15.4¢ change in the Denali share price represents the entire Bioasis market cap.

It's not a stretch of any kind to think that Bioasis can achieve similar clinical results with the xB3 Platform and our pipeline. The current share price of 35¢ is ridiculous. We should move up today on this Denali news because our technology is as good or better than theirs. We may not move up because, hey, we're Bioasis, but make no mistake, Denali is showing us what xB3 is worth.

Davenport

<< Previous
Bullboard Posts
Next >>